Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $43.01 +3.41 (+8.61%) Closing price 04:00 PM EasternExtended Trading$43.02 +0.01 (+0.01%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Merus Stock (NASDAQ:MRUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Merus alerts:Sign Up Key Stats Today's Range$38.40▼$43.3350-Day Range$39.60▼$49.1652-Week Range$37.77▼$61.61Volume821,004 shsAverage Volume699,224 shsMarket Capitalization$2.97 billionP/E RatioN/ADividend YieldN/APrice Target$85.31Consensus RatingBuy Company OverviewMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More… Remove Ads Merus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreMRUS MarketRank™: Merus scored higher than 47% of companies evaluated by MarketBeat, and ranked 605th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.34% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.34% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.70 News SentimentMerus has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Merus this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Stock News HeadlinesMerus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 1 at 8:00 AM | globenewswire.comMerus' (MRUS) Buy Rating Reaffirmed at GuggenheimMarch 29, 2025 | americanbankingnews.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 2, 2025 | Paradigm Press (Ad)Merus, Urban Sites unveil $26M Kenton County apartment projectMarch 27, 2025 | bizjournals.comMerus (MRUS) Gets a Buy from CitiMarch 22, 2025 | markets.businessinsider.comBuy Rating on Merus: Promising Potential of Petosemtamab in Combination with PD-1 Therapy for Head and Neck CancerMarch 21, 2025 | tipranks.comBank of America Securities Remains a Buy on Merus (MRUS)March 10, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)March 6, 2025 | markets.businessinsider.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $42.05 at the beginning of 2025. Since then, MRUS stock has increased by 2.3% and is now trading at $43.01. View the best growth stocks for 2025 here. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) issued its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The biotechnology company earned $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative net margin of 680.61% and a negative trailing twelve-month return on equity of 38.89%. When did Merus IPO? Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings2/27/2025Today4/02/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$85.31 High Stock Price Target$109.00 Low Stock Price Target$67.00 Potential Upside/Downside+98.3%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-680.61% Pretax Margin-659.93% Return on Equity-38.89% Return on Assets-31.16% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio8.32 Sales & Book Value Annual Sales$36.13 million Price / Sales82.24 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book6.97Miscellaneous Outstanding Shares69,090,000Free Float65,335,000Market Cap$2.97 billion OptionableOptionable Beta1.02 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:MRUS) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.